



For Release:

Press Contact:

Marjie Hadad

Media Liaison

Exalenz Bioscience

marjie@netvision.net.il

+972-54-536-5220

### Exalenz Granted US Patent for Liver Application of Company's BreathID Platform Technology

This is the first patent granted for company's method of  
evaluating the liver condition of patients utilizing its breath test device

Jersey City, New Jersey, August 21, 2013 ---- Exalenz Bioscience, ([TASE: EXEN](#)), developer of advanced diagnostic systems that use the patient's breath to assess gastrointestinal and liver conditions, announced today that the company was granted its first patent for a liver application of its technology. The patent was granted by the United States Patent and Trademark Office. Patent number [8,512,258](#) was granted to Exalenz for the BreathID Platform Technology's method of evaluating the liver condition of a patient.

Exalenz's breath test liver application is designed to evaluate the liver condition of a patient by computing and comparing breath test parameters, before and after ingestion of a test substrate in real-time, while collecting a continuous flow of the patient's breath, as described in the patent announced today. The technology has multiple diagnostic applications. For example: Exalenz conducted an extensive market survey which showed that there is a clear need for a simple, non-invasive test for detecting the onset of Clinically Significant Portal Hypertension (CSPH), an increase in blood pressure in the veins of the portal system caused by obstruction in the liver. Chronic high blood pressure is prevalent in advanced stages of chronic liver disease and affects liver function. Today, direct measurement of portal pressure is invasive, costly, inconvenient, and requires highly-skilled and experienced physicians to perform the procedure accurately.

"We are enthusiastic about today's patent. Exalenz intends to develop an impressive product pipeline based on the BreathID Technology Platform. Today's achievement marks the latest progress in this ongoing initiative," said Exalenz CEO Mr. Lawrence Cohen. "It has been a busy summer. In July, we launched the BreathID Hp for the detection and management of the H. pylori bacteria. We also established a new direct US sales team purposed to better service our

valued customers. We are looking forward to continuing the momentum and to more exciting developments in the fall.

#### About Exalenz Bioscience

Exalenz Bioscience develops advanced diagnostic systems that use the real-time, continuous flow of a patient's breath to diagnose and help manage digestive system and liver conditions. The company's flagship BreathID Hp product detects the presence of the *H. pylori* bacteria, the cause of various illnesses. The BreathID Hp system is FDA cleared and has a CE mark.

For more information: [www.breathid.com](http://www.breathid.com)

Follow us on [Twitter](#).

Message us on [LinkedIn](#)

Visit us on [Wikipedia](#)

*This news release may contain "forward-looking statements." Statements in this press release, which are not purely historical, are forward-looking statements including statements concerning the Company's business outlook or future economic performance, anticipated revenues, expenses or other financial items, plans and objectives related thereto, and assumptions or expectations relating to any future events, conditions, performance or other matters. Forward-looking statements are subject to risks, uncertainties and factors including, but not limited to, changing customer demands, changing regulatory requirements, customer acceptance of the Company's products, the impact of competitive products and pricing, dependence on existing management, that technology may not function as expected and general economic conditions. The Company assumes no obligation to update the information in this release.*